These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15572763)

  • 1. Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
    Tsurutani J; Dennis PA
    J Natl Cancer Inst; 2004 Dec; 96(23):1795; author reply 1795-6. PubMed ID: 15572763
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
    de Braud F; De Pas T; Spaggiari L; Veronesi G; Curigliano G; Noberasco C; Pelosi G
    J Natl Cancer Inst; 2005 Mar; 97(6):461-2; author reply 462-3. PubMed ID: 15770011
    [No Abstract]   [Full Text] [Related]  

  • 3. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
    Cappuzzo F; Magrini E; Ceresoli GL; Bartolini S; Rossi E; Ludovini V; Gregorc V; Ligorio C; Cancellieri A; Damiani S; Spreafico A; Paties CT; Lombardo L; Calandri C; Bellezza G; Tonato M; Crinò L
    J Natl Cancer Inst; 2004 Aug; 96(15):1133-41. PubMed ID: 15292385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?
    Pao W; Miller VA; Venkatraman E; Kris MG
    J Natl Cancer Inst; 2004 Aug; 96(15):1117-9. PubMed ID: 15292378
    [No Abstract]   [Full Text] [Related]  

  • 5. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
    Cappuzzo F; Hirsch FR; Rossi E; Bartolini S; Ceresoli GL; Bemis L; Haney J; Witta S; Danenberg K; Domenichini I; Ludovini V; Magrini E; Gregorc V; Doglioni C; Sidoni A; Tonato M; Franklin WA; Crino L; Bunn PA; Varella-Garcia M
    J Natl Cancer Inst; 2005 May; 97(9):643-55. PubMed ID: 15870435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
    Tracy S; Mukohara T; Hansen M; Meyerson M; Johnson BE; Jänne PA
    Cancer Res; 2004 Oct; 64(20):7241-4. PubMed ID: 15492241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?
    Cappuzzo F
    J Natl Cancer Inst; 2005 Jun; 97(12):868-9. PubMed ID: 15956643
    [No Abstract]   [Full Text] [Related]  

  • 8. Biomarkers of response to gefitinib in non-small-cell lung cancer.
    Carbone DP
    Nat Clin Pract Oncol; 2004 Dec; 1(2):66-7. PubMed ID: 16264818
    [No Abstract]   [Full Text] [Related]  

  • 9. A curious link between epidermal growth factor receptor amplification and survival: effect of "allele dilution" on gefitinib sensitivity?
    Kaye FJ
    J Natl Cancer Inst; 2005 May; 97(9):621-3. PubMed ID: 15870427
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
    Han SW; Kim TY; Jeon YK; Hwang PG; Im SA; Lee KH; Kim JH; Kim DW; Heo DS; Kim NK; Chung DH; Bang YJ
    Clin Cancer Res; 2006 Apr; 12(8):2538-44. PubMed ID: 16638863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
    Han SY; Zhao MB; Zhuang GB; Li PP
    Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib.
    Ando K; Ohmori T; Inoue F; Kadofuku T; Hosaka T; Ishida H; Shirai T; Okuda K; Hirose T; Horichi N; Nishio K; Saijo N; Adachi M; Kuroki T
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8872-9. PubMed ID: 16361577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).
    Kokubo Y; Gemma A; Noro R; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Shibuya M; Kudoh S
    Br J Cancer; 2005 May; 92(9):1711-9. PubMed ID: 15870831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer.
    Ochi N; Takigawa N; Harada D; Yasugi M; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
    Exp Cell Res; 2014 Mar; 322(1):168-77. PubMed ID: 24440771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
    Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
    BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
    Engelman JA; Jänne PA; Mermel C; Pearlberg J; Mukohara T; Fleet C; Cichowski K; Johnson BE; Cantley LC
    Proc Natl Acad Sci U S A; 2005 Mar; 102(10):3788-93. PubMed ID: 15731348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
    Sordella R; Bell DW; Haber DA; Settleman J
    Science; 2004 Aug; 305(5687):1163-7. PubMed ID: 15284455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment.
    Choi DY; You S; Jung JH; Lee JC; Rho JK; Lee KY; Freeman MR; Kim KP; Kim J
    Proteomics; 2014 Aug; 14(16):1845-56. PubMed ID: 24946052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.